Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Noretistherone

Classification: B

Drug products: Activelle, Activelle®, Cliovelle, Estalis, Estalis®, Eviana, Femanor®, Femasekvens®, Kliogest®, Mini-Pe®, Noresmea, Noriday, Novofem®, Orthonett® Novum, Primolut®-Nor, Sequidot®, Synfase®, Synfase® 28, Synphase, Triella, Trinovum, Trinovum®, Trinovum® 28, Trisekvens, Trisekvens®

ATC code: G03AA05, G03AB04, G03AC01, G03DC02, G03FA01, G03FB05

Summary

As the substance is only used by women, analyses on sex or gender differences have not been considered relevant.

Additional information

The approved indication for noretistherone alone or in combination with ethinylestradiol or estradiol is contraception [1-2]. Experimentally, the substance has been used by men in clinical studies of anticonception, commonly in combination with testosterone [3-4].

Updated: 2017-07-24

Date of litterature search: 2017-06-22

References

Mini-Pe (noretisteron). Summary of Product Characteristics. Medical Products Agency (MPA); 2006.
NORETHISTERONE (norethisterone). Drugs.com [www]. [cited 2017-06-22]. länk
Grimes DA, Lopez LM, Gallo MF, Halpern V, Nanda K, Schulz KF. Steroid hormones for contraception in men. Cochrane Database Syst Rev. 2012;3:CD004316. PubMed
Behre HM, Zitzmann M, Anderson RA, Handelsman DJ, Lestari SW, McLachlan RI et al. Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men. J Clin Endocrinol Metab. 2016;101:4779-4788. PubMed
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-06-20.] länk

Authors: Mia von Euler, Linnéa Karlsson Lind

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson